Corcept Therapeutics Incorporated (CORT)
| Market Cap | 2.05B |
| Revenue (ttm) | 352.89M |
| Net Income (ttm) | 106.45M |
| Shares Out | 115.45M |
| EPS (ttm) | 0.83 |
| PE Ratio | 21.42 |
| Forward PE | 18.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 675,335 |
| Open | 17.01 |
| Previous Close | 17.19 |
| Day's Range | 16.78 - 17.85 |
| 52-Week Range | 15.83 - 31.18 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 25.50 (+43.4%) |
| Earnings Date | Feb 7, 2022 |
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 25.50, which is an increase of 43.42% from the latest price.
News
Moore Kuehn, PLLC Encourages Investors of Corcept Therapeutics, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - January 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Corcept Therapeutics...
Corcept Investor Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...
Corcept Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
New York, New York--(Newsfile Corp. - January 19, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT). Such inve...
Corcept Update
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...
Wall Street Analysts See a 26% Upside in Corcept (CORT): Can the Stock Really Move This High?
The mean of analysts' price targets for Corcept (CORT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...
CORT vs. ZTS: Which Stock Is the Better Value Option?
CORT vs. ZTS: Which Stock Is the Better Value Option?
2 Under-the-Radar Biotech Picks to Buy For The Long Haul
These quiet biotechs are tightly focused and practically alone in their markets.
Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
MENLO PARK, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat ...
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholde...
NEW YORK--(BUSINESS WIRE)-- #CORT--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (“Corcept” or the...
Why Corcept Therapeutics Stock Was Up 11.6% Friday
Investors may be looking for a bargain after the company was hit with bad news this week.
Why Corcept Therapeutics Tanked by Almost 17% Today
A U.S. attorney is interested in the company for the wrong reasons.
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat s...
Why Is Corcept (CORT) Up 6.6% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Corcept Therapeutics (CORT) Q3 Earnings Top Estimates
Corcept (CORT) delivered earnings and revenue surprises of 26.32% and -1.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update
MENLO PARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on No...
Corcept Therapeutics (CORT) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moore Kuehn, PLLC Encourages Investors of Corcept Therapeutics, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - October 4, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Corcept Therapeutics,...
Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology ( ESMO21 )...
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with R...
MENLO PARK, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Pati...
MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...
William Guyer to join Corcept as Chief Development Officer
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.